Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genflow Biosciences Plc ( (GB:GENF) ) just unveiled an update.
Genflow Biosciences Plc announced that as of 31 October 2025, the company’s total issued share capital consists of 493,547,942 Ordinary Shares, all with voting rights. This information is crucial for shareholders to determine their notification requirements under the Financial Conduct Authority’s rules, potentially impacting investment decisions and stakeholder engagement.
More about Genflow Biosciences Plc
Genflow Biosciences Plc, founded in 2020 and headquartered in the UK with R&D facilities in Belgium, is a biotechnology company focused on pioneering gene therapies to slow down the aging process. Their primary product, GF-1002, utilizes a centenarian variant of the SIRT6 gene, with ongoing clinical trials to evaluate its efficacy in aged dogs and potential benefits for treating MASH, a prevalent chronic liver disease.
Average Trading Volume: 6,735,453
Technical Sentiment Signal: Buy
For an in-depth examination of GENF stock, go to TipRanks’ Overview page.